Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.11
Previous CloseN/A
Volume2.00
Average Volume (3M)53.09K
Market Cap
$15.09K
Enterprise Value$1.94M
Total Cash (Recent Filing)$2.00K
Total Debt (Recent Filing)$520.00K
Price to Earnings (P/E)―
Beta-0.57
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding50,297,450
10 Day Avg. Volume87,590
30 Day Avg. Volume53,093
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap128.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.92
Enterprise Value/Ebitda-0.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery low absolute debt limits near-term interest and refinancing pressure, preserving more flexibility than a heavily leveraged clinical-stage company. This provides some balance-sheet support while BPTH funds research and development, even though negative equity remains a major constraint.
Reduced Cash BurnThe sharp reduction in operating and free cash outflow indicates improved cash discipline or lower spending intensity compared with 2024. If sustained, a lower burn rate could extend available resources and reduce the frequency of external financing needed to support development activities.
Proprietary Oncology PlatformA proprietary delivery approach may provide a platform for developing multiple oncology candidates rather than relying on a single asset. Its focus on RNAi-based therapeutics and hematologic malignancies gives BPTH a defined scientific strategy that could support longer-term pipeline development.
Bears Say
No Commercial RevenueThe absence of revenue shows that BPTH remains dependent on clinical development and has not established commercial product sales. Without recurring operating revenue, progress toward financial sustainability depends on successful candidate development, regulatory approval, and eventual commercialization.
Negative Equity And Asset DepletionNegative equity and the steep decline in total assets indicate substantial capital depletion and materially reduce financial flexibility. This weakens the balance-sheet base available to fund clinical programs and increases the company’s dependence on obtaining additional capital over time.
Persistent Losses And Cash OutflowsLarge recurring net losses and consistently negative operating cash flow show that BPTH has not yet achieved operating leverage or self-funded growth. Continued cash consumption can constrain research progress and require external financing, creating ongoing funding risk for the business.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $15.09K.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 17 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on Aug 18, 2026. The company reported -$0.088 earnings per share for the quarter.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.088 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Technical Analysis
Matinas BioPharma
―
Cellectar Biosciences
―
Moleculin Biotech
―
Nucana
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.50% Other Institutional Investors
99.50% Public Companies and
Individual Investors